Moleculin Biotech (NASDAQ:MBRX) Trading Down 3.3% – What’s Next?

Moleculin Biotech, Inc. (NASDAQ:MBRX)’s stock price traded down 3.3% on Tuesday . The company traded as low as $2.26 and last traded at $2.32. Approximately 240,950 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 1,117,771 shares. The stock had previously closed at $2.40.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Wall Street Zen lowered Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moleculin Biotech has an average rating of “Hold” and an average target price of $22.00.

Moleculin Biotech Price Performance

The firm has a market cap of $12.39 million, a price-to-earnings ratio of -0.13 and a beta of 1.75. The firm’s 50 day moving average price is $2.59 and its 200-day moving average price is $2.99.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Thursday, May 14th. The company reported ($3.54) earnings per share for the quarter, missing the consensus estimate of ($2.33) by ($1.21). Analysts expect that Moleculin Biotech, Inc. will post -5.1 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent filing with the SEC. 15.52% of the stock is currently owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.